The top 20 highest-paid biopharma CEOs of 2018


As in past years, FiercePharma has tracked yearly data to compile the top CEO pay packages in biopharma, ranging from nearly $60M to $16M in 2018, and they’ve pointed out some notable trends. First, no women made the list. Big Pharma’s only female CEO, GlaxoSmithKline’s Emma Walmsley, fell short with a pay package of $7.75M.

However, some of her Big Pharma peers also fell short. Last year, Novartis’ Vas Narasimhan pulled in $9.9M, Roche’s Severin Schwan pulled in about $11.77M, and Sanofi’s Olivier Brandicourt took a pay cut to $8.2M. But perhaps the biggest change in 2018 is the emergence of biotech CEOs scattered throughout the list. The last trend noted is that company size didn’t exactly correlate with a bigger payday. The top 20 highest-paid biopharma CEOs of 2018 are listed below:

  1. Stéphane Bancel, Moderna Therapeutics
  2. Kåre Schultz, Teva
  3. John Oyler, BeiGene
  4. Len Schleifer, Regeneron
  5. John Milligan, Gilead Sciences
  6. Nick Leschly, Bluebird Bio
  7. Richard Gonzalez, AbbVie
  8. Kenneth Frazier, Merck & Co.
  9. Alex Gorsky, Johnson & Johnson
  10. Paul Campanelli, Endo
  11. Ian Read, Pfizer
  12. Giovanni Caforio, Bristol-Myers Squibb
  13. Jeffrey Leiden, Vertex Pharmaceuticals
  14. Robert Bradway, Amgen
  15. Clay Siegall, Seattle Genetics
  16. David Ricks, Eli Lilly
  17. Richard Pops, Alkermes
  18. Ludwig Hantson, Alexion Pharmaceuticals
  19. Mark Alles, Celgene
  20. Michel Vounatsos, Biogen

Read the full report at…


Comments are closed.

More in Ashton Tweed Connection
Insys files for bankruptcy on the heels of $225M kickback settlement with the feds

Insys Therapeutics settled with the feds for $225M on federal kickback charges, but things continue to escalate for the opioid...